Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a co.

Evommune Announces $125 Million Private Placement

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of.

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domai.

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

PALO ALTO, Calif.--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. “The recent completion of our IPO puts us in a strong position to deliver on the years ahead, with three Phase 2 readouts across our two lead programs, EVO756 and EVO301, expe.